自身免疫性淋巴增殖综合征的18F-FDG PET影像特征
该前瞻性研究纳入76例ALPS/ALPS样患者行FDG PET,评估14个淋巴结区域、肝和脾的摄取。FAS突变伴与不伴淋巴瘤组最高SUVmax差异有统计学意义但存在重叠,无法个体化区分淋巴瘤;82%患者脾肝摄取比大于1。
要点
- FAS突变ALPS伴与不伴淋巴瘤的FDG摄取差异有统计学意义但重叠明显,不能据此区分个体。
- 82%的ALPS患者脾肝摄取比大于1。
- 各ALPS亚组间FDG生物分布模式相似。
核心结论
- FAS突变ALPS伴与不伴淋巴瘤组FDG摄取差异有统计学意义,但显著重叠使个体化区分淋巴瘤不可行。
研究设计与样本
- 前瞻性评估76例ALPS/ALPS样患者,包括FAS胚系突变伴淋巴瘤4例、不伴淋巴瘤50例、FAS体细胞突变6例、ALPS-未知6例及其他10例,均行FDG PET。
- 测定14个淋巴结区域、肝和脾的摄取。
主要发现
- 76例中除1例外,FDG PET均显示多淋巴结区域摄取。
- FAS突变不伴淋巴瘤组最高SUVmax中位(范围)为9.2(4.3-25),伴淋巴瘤组为16.2(10.7-37.2)。
- FAS体细胞突变组最高SUVmax中位(范围)为7.6(4.6-18.1),ALPS-未知组为11.5(4.8-17.2),其他遗传突变组为5.5(0-15.3)。
- 82%患者脾肝摄取比大于1。
临床怎么用
- FDG PET可用于显示ALPS患者的多淋巴结区域摄取及脾肝摄取比升高,但不应单独用于区分淋巴瘤与良性淋巴结病。
局限性
- FAS突变伴与不伴淋巴瘤组FDG摄取显著重叠,视觉表现亦重叠,无法个体化鉴别淋巴瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Autoimmune lymphoproliferative syndrome (ALPS) is a rare immune dysregulatory condition, usually presenting in childhood with massive lymphadenopathy, splenomegaly, and an increased incidence of lymphoma. Methods to differentiate between benign ALPS adenopathy and lymphoma are needed. To this end, we evaluated the usefulness of FDG PET. METHODS: We prospectively evaluated 76 ALPS/ALPS-like patients including FS-7-associated surface antigen (FAS) germline mutation with (n = 4) and without lymphoma (n = 50), FAS-somatic (n = 6), ALPS-unknown (n = 6), and others (n = 10) who underwent FDG PET. Uptakes in 14 nodal sites, liver, and spleen were determined. RESULTS: In 76 ALPS patients, FDG PET showed uptake in multiple nodal sites in all but 1 patient. The highest SUVmax values in FAS mutation without lymphoma, FAS mutation with lymphoma, FAS somatic, ALPS-unknown, and other genetic mutations were a median (range) 9.2 (4.3-25), 16.2 (10.7-37.2), 7.6 (4.6-18.1), 11.5 (4.8-17.2), and 5.5 (0-15.3), respectively. Differences between uptake in the FAS group with and without lymphoma were statistically significant, but overlapped, making discrimination between individuals with/without lymphoma impossible. The spleen:liver uptake ratio was greater than 1 in 82% of patients. CONCLUSIONS: While statistically significant differences were observed in FAS mutation ALPS with and without lymphoma, the significant overlap in FDG uptake and visual appearance in many patients prevents discrimination between patients with and without lymphoma. Similar patterns of FDG biodistribution were noted between the various ALPS subgroups.
引用
- Carrasquillo JA, Chen CC, Price S, et al. 18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome. Clin Nucl Med. 2019. PMID: 31689275. doi:10.1097/RLU.0000000000002816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。